Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.

Abstract: Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.

Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.

Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

Abstract: A method for producing injectable pharmaceutical formulations of blood-derived protein materials includes the steps of fractioning the source material in a polymer/salt aqueous two-phase system in the presence of phenol, purifying the top phase of the system by means of precipitation with caprylic acid and purifying the bottom phase by means of thermocoagulation, increasing the purity of the materials in both phases through chromatography, removing viral particles by means of the nanofiltration of both preparations, and formulating, stabilizing, and packaging the resulting materials.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.

Abstract: A method of purifying a desired protein from a preparation includes providing the preparation in a form having less than about 5% of the chromatin residing in the original production medium, contacting the preparation with a nonionic organic polymer in an amount sufficient to cause the desired protein to precipitate or adsorb on a nonionic hydrophilic surface, and adjusting a salt concentration before or during the contacting step, the adjusting step providing a sufficient salt concentration to produce a conductivity greater than physiological conductivity.

Abstract: The present invention provides a process for the isolation of one or more proteins) from a protein solution. The process comprising the steps of: a) providing a protein solution comprising one or more specific proteins) and having a preset pH and a preset ionic strength or conductivity, b) applying the protein solution to a packed bed or expanded bed column comprising an adsorbent, and c) obtaining one or more proteins) from the column; wherein the protein solution has been supplemented with an alcohol.

Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.

Abstract: The current invention is directed to a chromatography column separator which separates the chromatography column in an upper chromatography column chamber and a lower chromatography column chamber, and which has a variable position within the chromatography column, and which is embedded by the chromatography material. The separator allows the replacement of the chromatography material in the upper chromatography column chamber without the need to replace the chromatography column material in the lower chromatography column chamber and it allows also the combination of two different chromatography materials with different chromatographical functional groups in one chromatography column.

Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.

Abstract: A method for extracting recombinant human serum albumin (rHSA) from transgenic rice grain is provided, comprising the steps of: 1) grinding dehusked rice containing rHSA into milled rice grain with a fineness of 80˜120 mesh, which is mixed with a extraction buffer in a w/v ratio of 1:5, then extracting at 55˜60° C. for 1˜3 hours to obtain mixture I; said extraction buffer comprises 10˜30 mM phosphate buffer, 10˜20 mM sodium acetate, 15˜30 mM ammonium sulfate and 5˜20 mM sodium caprylate and has a pH of 6.5˜8; 2) adjusting the pH of mixture I to 4.0˜4.5, followed by precipitating at room temperature for 3˜12 hours to obtain mixture II; 3) filtering the mixture II and collecting the filtrate, to obtain a solution containing high concentration of rHSA. The concentration of rHSA in the resultant solution is 650˜660 ?g/mL, which increases by 1.15 times comparing to the extraction amount before improvement, and the amount of non-target protein is reduced by 2.46 times.

Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.

Abstract: The present invention relates to a method for isolating and purifying nucleic acids, preferably comprising genomic DNA, from biological samples comprising the steps of lysing the sample using a lysis buffer comprising a source of anionic surfactant ions, optionally disintegrating the RNA present in the lysate, precipitating the surfactant ions from the lysate, and separating the nucleic acids from the precipitate and further contaminants by size-exclusion chromatography. The invention furthermore relates to a lysis buffer, a method of lysing cells and a kit for the isolation and purification of nucleic acids.

Abstract: A compound may generally comprise the formula: wherein R1 is independently selected from C2-C10 alkyl or substituted alkyl, R2 is independently selected from the group consisting of —H and C1-C6 alkyl or substituted alkyl, X is selected from the group consisting of —NH— and —O—, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.

Abstract: The present invention provides a chromatography medium comprising one or more electrospun polymer nanofibres which form a stationary phase comprising a plurality of pores through which a mobile phase can permeate and use of the same in chromatography, such as the isolation of recombinant proteins, monoclonal antibodies, viral vaccines and plasmid DNA. The invention further provides for the use of the chromatographic medium in a simulated moving bed system.

Abstract: This invention concerns the preparation and use of novel polymeric chromatographic media and preferably mixed mode polymeric chromatographic media. In accordance with the present invention, polymeric media is prepared using polymeric particles derivatized with polyethyleneimine, and preferably such polyethyleneimine derivatized polymeric particles further functionalized with appropriate reactants. The polymeric chromatographic media is especially useful for bioseparations.

Abstract: Methods and kits for diagnosis and prognosis using biomarkers comprising albumin-bound protein/peptide complex (ABPPC).

Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: A method for producing injectable pharmaceutical formulations of blood-derived protein materials includes the steps of fractioning the source material in a polymer/salt aqueous two-phase system in the presence of phenol, purifying the top phase of the system by means of precipitation with caprylic acid and purifying the bottom phase by means of thermocoagulation, increasing the purity of the materials in both phases through chromatography, removing viral particles by means of the nanofiltration of both preparations, and formulating, stabilizing, and packaging the resulting materials.

Abstract: Provided are peptide analogues of PA-IL and compositions containing them. The PA-IL peptide analogues have altered carbohydrate binding specificity relative to a PA-IL of SEQ ID NO:1, and thus the analogues contain amino acid substitutions in SEQ ID NO:1. The substitutions can be at positions 50, 52 and 53 of SEQ ID NO:1 and can include combinations of amino acid substitutions at those positions Also included are methods for detecting changes in the glycosylation of carbohydrates and for separating biomolecules which contain glycoproteins or glycoconjugates.

Abstract: Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.

Abstract: The present invention relates to a sentinel lymph node marker comprising an albumin; a radioactive isotope and/or near infrared dye which is bound to the albumin; and a visible dye which is bound to the albumin, a preparation method thereof, a kit for multimode imaging of a sentinel lymph node to prepare the sentinel lymph node marker, and a method for multimode imaging of a sentinel lymph node using the same. The sentinel lymph node marker of the invention remains in the sentinel lymph node for a long period of time and allows for multimode imaging of the sentinel lymph node. Thus, using this marker the sentinel lymph node can be accurately identified in vivo by near infrared imaging and/or gamma imaging without incision of skin, and the location of the identified sentinel lymph node can be precisely identified with the naked eye during a surgical operation of removing the identified sentinel lymph node.

Abstract: The various embodiments herein provide a method of synthesizing a multi-mode cancer targeted nanoparticles. The method comprises the steps of preparing a plurality of nanoparticles and covalently conjugating monoclonal antibodies on surface of the prepared plurality of nanoparticles. The plurality of nanoparticles consists of a protein and a drug. The protein is Human Serum Albumin protein (HSA) and the drug is methotrexate. The monoclonal antibodies are anti-MUC1 nanobodies. According to an embodiment herein, a multi-mode cancer targeted nanoparticles comprising a plurality of cross linked nanoparticles of protein and drug molecules and covalently linked molecules of monoclonal antibodies. The molecules of monoclonal antibodies are linked on a surface of the plurality of cross linked nanoparticles.

Abstract: Semi-interpenetrating polymeric networks are described. More specifically, the semi-interpenetrating polymeric networks include at least two polymers that are closely associated. The first polymer is an ionic polymer that is not crosslinked. The second polymer is a cross-linked polymer that can be either another ionic polymer or a non-ionic polymer. Methods of making the semi-interpenetrating polymeric networks, articles containing the semi-interpenetrating polymeric networks, and methods of using the semi-interpenetrating polymeric networks are also described. The semi-interpenetrating polymeric networks can function as ion exchange resins.

Abstract: Provided herein are novel reagents and their use in color-producing detection systems for performing diagnostic tests and analytical assays.

Abstract: A new method is disclosed for the exfoliation of hexagonal boron nitride into mono- and few-layered nanosheets (or nanoplatelets, nanomesh, nanoribbons). The method does not necessarily require high temperature or vacuum, but uses commercially available h-BN powders (or those derived from these materials, bulk crystals) and only requires wet chemical processing. The method is facile, cost efficient, and scalable. The resultant exfoliated h-BN is dispersible in an organic solvent or water thus amenable for solution processing for unique microelectronic or composite applications.

Abstract: Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R1 is independently selected from —(CH2)0-9CH3, R2 is selected from the group consisting of —H and —(CH2)0-5CH3, Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.

Abstract: Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R1 is independently selected from —(CH2)0-9CH3, R2 is selected from the group consisting of —H and —(CH2)0-5CH3, Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.

Abstract: Methods of harvesting proteins directly from bioreactors to avoid at several steps in the purification of recombinant drugs are disclosed.

Abstract: A method for separating and purifying recombinant human serum albumin (rHSA) from transgenic rice grain, sequentially comprising the steps of: 1) subjecting crude extract of rHSA to cation exchange chromatography to obtain primary product I; 2) subjecting the primary product I to anion exchange chromatography to obtain secondary product II; 3) subjecting the secondary product II to hydrophobic chromatography to obtain purified rHSA. The method may further comprise a step of ceramic hydroxyapatite chromatography prior to the hydrophobic chromatography. The method has the advantages of low cost and easy operation. The resultant rHSA has a purity of about 99% by HPLC.

Abstract: An improved method for purifying albumin, a variant or fragment thereof, a fusion protein comprising albumin, a variant or fragment thereof, or a conjugate comprising albumin, a variant or fragment thereof is disclosed.

Abstract: A method of purifying biomolecules with an anion exchanger containing a membrane having a surface having a polymer such as a primary or secondary amine ligand formed thereon, such as polyallylamine. The feedstock is introduced to the exchanger in the presence of one or more ionic-modifiers by themselves or in combination with monovalent salt. The ionic modifier alters the binding ability of the primary amines such that they retain a significant binding capacity for highly charged species such as DNA but lose part or almost all of their binding capacity for less charged species such as viruses or proteins at pH above the pI of the virus or protein.

Abstract: Described herein is a composition and process for synthesizing a human serum albumin (HSA) based plasma replacement composition that includes a polymerized HSA (PolyHSA) that is chemically stabilized by the reduction of Schiff bases. The PolyHSA may have a molecular weight of at least about 100 kDa and may optionally have a cross-linker to HSA molar ratio of at least about 10:1. The PolyHSA composition is useful for restoring a subject's circulatory volume.

Abstract: Fluorescent dye compounds of formula (I) are disclosed. These compounds are useful as they interact with organic compounds in a manner such that excitation with certain wavelengths of light results in fluorescent emission. Detection and/or monitoring of the fluorescence provides a means for the detection or quantification of organic compounds when bound to these fluorescent dye compounds. Formula (I), wherein: each of R, R? and R? is a hydrogen atom, halogen atom or a straight or branched C1-20 alkyl, alkenyl or alkynl group optionally substituted with one or more halogen, hydroxyl, and/or oxy group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms.

Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.

Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterized in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.

Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.

Abstract: Provided are methods of making carrier polypeptide that include incorporating a first unnatural amino acid into a carrier polypeptide variant, incorporating a second unnatural amino acid into a target polypeptide variant, and reacting the first and second unnatural amino acids to produce the conjugate. Conjugates produced using the provided methods are also provided. In addition, orthogonal translation systems in methylotrophic yeast and methods of using these systems to produce carrier and target polypeptide variants comprising unnatural amino acids are provided.

Abstract: This invention is related to preparation of photosensitive ruthenium based aminoacid monomers and oligomers, aminoacid monomer-protein cross-linking using photo sensitat ion and conjugation on micro and nano-structures by ruthenium-chelate based monomers. Its vast range biotechnolgy applications of multifunctional, biocompatible, stabilE and specific micro and nanobio-conjugates, which will stand-alone or simultaneously enable (i) both purification and determination, (ii) both targeting and imaging and theranostics and (iii) catalysis and determination. The construction and method of preparation is applicable to silica materials, superparamagnetic particles, QDs, CNTs, Ag/Au nanoparticles and Au surfaces and polymeric materials. The photosensitive aminoacid monomer linkers can react via chemically and biocompatible to a lot of different micro and nano-surface and then to the protein when they act as a single-step cross-linking reaction using irradiation.

Abstract: The present invention relates to animal feed additives and detection thereof in feed products. Additionally, the present invention relates to yeast cell wall components, their methods of isolation, and compositions and methods for the immunological detection thereof.

Abstract: A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps.

Abstract: A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a crosslinking reaction to form a 3-dimensional matrix of the biomaterial.

Abstract: A process for the production of a microparticle or a nanoparticle of a chemical compound comprising the steps of providing a solution of said chemical compound in a first liquid; providing a second liquid in which said chemical compound is insoluble or substantially insoluble; combining said liquids in a region of high shear thereby causing formation of said particles; and isolating said particles of said compound. The processing time of a coacervation style process can be reduced and the yield can be substantially increased both by control of the precipitation step which allows for desolvation step to be dispensed with leading to significant process time reduction. The invention also provides a molecular mixing unit comprising an outer body defining a mixing zone; a shear means to provide shear liquid in said mixing zone; at least one fluid inlet means for a first liquid; at least one fluid inlet means for a second liquid and a fluid outlet means.

Abstract: A new method is disclosed for the exfoliation of hexagonal boron nitride into mono- and few-layered nanosheets (or nanoplatelets, nanomesh, nanoribbons). The method does not necessarily require high temperature or vacuum, but uses commercially available h-BN powders (or those derived from these materials, bulk crystals) and only requires wet chemical processing. The method is facile, cost efficient, and scalable. The resultant exfoliated h-BN is dispersible in an organic solvent or water thus amenable for solution processing for unique microelectronic or composite applications.